Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy

Oncology Reports

Volumn 24, Issue 4, 2010, Pages 1049-1058

  Murray, Alexandra ^a,b   Little, Samantha J ^a   Stanley, Paul ^b   Maraveyas, Anthony ^a,b,c   Cawkwell, Lynn ^a,c  

^a UNIVERSITY OF HULL   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Angiogenesis inhibitors; Endothelial cells; Low dose chemotherapy; Metronomic chemotherapy; Sorafenib

Indexed keywords

ENDOTHELIAL CELL ANTIBODY; ETOPOSIDE; NAVELBINE; PACLITAXEL; SORAFENIB; TEMOZOLOMIDE;

ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MELANOMA; MICROVASCULATURE; PRIORITY JOURNAL; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIAL CELLS; ETOPOSIDE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; PYRIDINES;

EID: 77957326888     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000954     Document Type: Article

References (32)

1. Le Tourneau C, Faivre S and Raymond E: New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev 34: 37-48, 2008.
2. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R and Taraboletti G: The microtubule-affecting drug paclitaxel has anti-angiogenic activity. Clin Cancer Res 2: 1843-1849, 1996.
3. Pasquier E, André N and Braguer D: Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr Cancer Drug Targets 7: 566-581, 2007.
4. Stoelting S, Trefzer T, Kisro J, Steinke A, Wagner T and Peters SO: Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients. In Vivo 22: 831-836, 2008.
5. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS and Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886, 2000.
6. Ma J and Waxman DJ: Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7: 3670-3684, 2008.
7. Shaked Y and Kerbel RS: Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 67: 7055-7058, 2007.
8. Kerbel RS and Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436, 2004.
9. Lam T, Hetherington JW, Greenman J and Maraveyas A: From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials. Anticancer Drugs 17: 113-121, 2006.
10. Pasquier E, Honoré S and Braguer D: Microtubule-targeting agents in angiogenesis: where do we stand? Drug Resist Updat 9: 74-86, 2006.
11. Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, Viacava P, Naccarato AG, Kerbel RS, Danesi R, Del Tacca M and Allegrini G: Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 98: 1619-1629, 2008.
12. Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G and Kerbel RS: Highly efficacious non-toxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 66: 3386-3391, 2006.
13. Scharovsky OG, Mainetti LE and Rozados VR: Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol 16: 7-15, 2009.
14. Gasparini G: Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2: 733-740, 2001.
15. Blansfield JA, Caragacianu D, Alexander HR III, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE and Libutti SK: Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 14: 270-280, 2008.
16. Ma J and Waxman DJ: Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther 7: 79-89, 2008.
17. Lam T, Hetherington JW, Greenman J, Little S and Maraveyas A: Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth. Acta Oncol 46: 1169-1177, 2007.
18. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E and Colleoni M: Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26: 4899-4905, 2008.
19. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ and Oza AM: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago and Princess Margaret Hospital phase II consortia. J Clin Oncol 26: 76-82, 2008.
20. Bocci G, Nicolaou KC and Kerbel RS: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62: 6938-6943, 2002.
21. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R and Pazdur R: Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12: 7271-7278, 2006.
22. Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R and Pazdur R: Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14: 95-100, 2009.
23. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140, 2008.
24. Kurzen H, Schmitt S, Naher H and Mohler T: Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14: 515-522, 2003.
25. Wang J, Lou P, Lesniewski R and Henkin J: Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14: 13-19, 2003.
26. Zhang M, Tao W, Pan S, Sun X and Jiang H: Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts. Anticancer Drugs 20: 355-363, 2009.
27. Bouis D, Hospers GA, Meijer C, Molema G and Mulder NH: Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis 4: 91-102, 2001.
28. Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, Cihon F, Lathia C and Schwartz B: Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/ 7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16: 1688-1694, 2005.
29. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan M, Batra V and Cutler D: Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81: 1022-1030, 1999.
30. Malingre MM, Terwogt JM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, Huinink WW, Swart M, Lieverst J and Schellens JH: Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol 18: 2468-2475, 2000.
31. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I and Puozzo C: Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12: 1643-1649, 2001.
32. Sessa C, Zucchetti M, Cerny T, Pagani O, Cavalli F, De Fusco M, De Jong J, Gentili D, McDaniel C, Prins C, Schacter L, Winograd B and D'Incalci M: Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J Clin Oncol 13: 200-209, 1995.